Person Centered Nursing Homes: Impact Assessment Of Centered Person Care In Nursing Homes

Overview

Cohort Observational Study. The study will assess differences in quality of life, well-being and mood between persons living in a nursing home following usual care and persons living in nursing homes following a centered person care model. Initially, the follow up will last 6 months, with the possibility to be extended.

Full Title of Study: “Residències Centrades en Les Persones (RECENPE): avaluació de l’Impacte d’un Model d’ACP en residències Per Persones Grans”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2018

Interventions

  • Other: ACP intervention
    • The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions: – Attention to the person based on: Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences. Respect and acknowledge of the person. Promotion of the autonomy. Personalized treatment, with tailored attention and integrative cures Protection of physical well-being, preventing damages and risks and promoting healthy habits. Promotion of independence on daily activities. Protection of privacy and personal matters – Positive environment based on: Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons. Social relationships, with proximity and collaboration with families. Friendly organization, with empathetic professionals empowering users.

Arms, Groups and Cohorts

  • Control
    • The control group is made by persons living in nursing homes under usual care

Clinical Trial Outcome Measures

Primary Measures

  • Thriving in nursing homes
    • Time Frame: 0, 6 months
    • Thriving in nursing homes will be assessed with the Thriving of Older People Assessment Scale (TOPAS). Investigators will assess the change between groups.
  • Quality of life
    • Time Frame: 0, 6 months
    • Quality of life will be assessed with the Euroqol 5D-5L. Investigators will assess the change between groups.
  • Well-being
    • Time Frame: 0, 6 months
    • Well-being will be assessed by the WHO (Five) Well Being Index (1998 version). Investigators will assess the change between groups.

Secondary Measures

  • Depressive symptoms
    • Time Frame: 0, 6 months
    • Cognitive impairment affects the assessment of depressive symptoms. For this reason, according to their stage using the Reisberg Global Deterioration Scale, investigators will assess the presence or absence of depressive symptoms with two tools stage 0 to 4: investigators will consider that a person has depressive symptoms with a score of 6 or more using the 15 items Yesavage Geriatric Depression Scale, stage 5 to 7: investigators will consider that a person has depressive symptoms with a score of 11 or more using the Cornell Depression Scale. Investigators will assess the change in the prevalence of depressive symptoms between groups.
  • Neuropsychiatric inventory
    • Time Frame: 0,6 months
    • Neuropsychiatric symptoms will be assessed with the Brief Neuropsychiatric inventory(NPI-Q). Investigators will assess the change between groups.

Participating in This Clinical Trial

Inclusion Criteria

  • Persons living in nursing homes – Consent from the person (or legal representative, if the person is not able) Exclusion Criteria:

  • Terminal illness – Living temporary in a nursing home

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Fundacio Salut i Envelliment UAB
  • Collaborator
    • SUMAR empresa d’acció social de Catalunya
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Xavier Rojano Luque, MD, Principal Investigator, Fundació Salut i Envelliment UAB
  • Overall Contact(s)
    • Xavier Rojano Luque, MD, 93 433 50 53, xavier.rojano@uab.cat

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.